Blair William & Co. IL Trims Stock Holdings in Glaukos Co. (NYSE:GKOS)

Blair William & Co. IL lessened its holdings in shares of Glaukos Co. (NYSE:GKOS) by 1.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 47,404 shares of the medical instruments supplier’s stock after selling 669 shares during the period. Blair William & Co. IL’s holdings in Glaukos were worth $7,108,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Mutual of America Capital Management LLC grew its position in shares of Glaukos by 1.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock worth $1,252,000 after buying an additional 89 shares in the last quarter. HighTower Advisors LLC grew its holdings in Glaukos by 2.8% during the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock worth $495,000 after acquiring an additional 91 shares in the last quarter. Louisiana State Employees Retirement System increased its position in shares of Glaukos by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock worth $4,003,000 after purchasing an additional 100 shares during the last quarter. Handelsbanken Fonder AB raised its stake in shares of Glaukos by 0.7% in the 4th quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier’s stock valued at $2,204,000 after purchasing an additional 100 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Glaukos by 2.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,956 shares of the medical instruments supplier’s stock worth $1,427,000 after purchasing an additional 231 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Trading Down 1.6 %

Glaukos stock opened at $101.97 on Friday. Glaukos Co. has a 52-week low of $88.16 and a 52-week high of $163.71. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $5.77 billion, a price-to-earnings ratio of -35.53 and a beta of 0.99. The firm has a 50-day moving average price of $130.52 and a two-hundred day moving average price of $135.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Sell-side analysts expect that Glaukos Co. will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Morgan Stanley lowered Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a report on Monday, December 2nd. UBS Group began coverage on Glaukos in a report on Friday, December 6th. They issued a “buy” rating and a $182.00 price target for the company. Piper Sandler restated an “overweight” rating and set a $180.00 price objective (up from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Stephens upgraded shares of Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Stifel Nicolaus increased their target price on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $163.25.

Insider Transactions at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Alex R. Thurman sold 1,520 shares of the firm’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the transaction, the chief financial officer now owns 53,431 shares in the company, valued at $5,708,568.04. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.